Research and Markets (http://www.researchandmarkets.com/reports/c41302) has announced the addition of "Cross Border Alliances in Biopharma Industry - Survey Report on Indian Companies" to their offering.
The Indian biopharmaceutical industry is moving up across the value chain and establishing itself as a basic research-driven, export-oriented industry, providing wide range of value added quality products and services. The industry is fast emerging as a favored destination for many overseas companies especially in the US and EU. In the last two decades, India has emerged as a preferred destination for quality production of active pharmaceutical ingredient (API) coupled with cost effectiveness.
At present, India has the largest number of US FDA approved facilities in the world next only to the US. The industry provides better manufacturing services as it has good infrastructure for producing biotechnology products in line with the global standards. The Indian industry is now looking for overseas collaboration and alliances to leverage these advantages.
To understand the Indian biopharmaceutical industry's views on cross-border alliances, a web-based survey was conducted to capture information on the companies, their plans for entering new markets and leveraging partnerships and alliances for growth and profitability. The survey questionnaire was completed by respondents from Indian companies, of whom 68% were key decision makers. Survey parameters included the strategies of the companies for market expansion, in short run as well as medium term, plans for outsourcing and the types of business models preferred for alliances. This report is useful for the companies to understand the perspectives of the Indian players so as to enable them to formulate the alliance strategies.
Key Topics Covered Include:
-- Executive summary
-- Objectives of the study
-- Scope of the report and key findings
-- Approach and methodology
-- Analysis and discussion
-- General information
For more information visit http://www.researchandmarkets.com/reports/c41302